Hematopoietic Stem Cell Transplantation in Patients with Hemoglobinopathies

References

• Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci. 1998;850:270–275.
   PubMed Web of Science ®Google Scholar
• Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplant. 2016;51(4):536–541.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Ertem M, Cetin M, et al. HLA-matched family hematopoietic stem cell transplantation in children with beta thalassemia major: the experience of the Turkish Pediatric Bone Marrow Transplantation Group. Pediatr Transplant. 2012;16(8):846–851.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417–421.
   PubMed Web of Science ®Google Scholar
• Strocchio L, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin North Am. 2018;32(2):317–328.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Deotare U, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(8):889–894.
   PubMed Web of Science ®Google Scholar
• Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011;117(5):1745–1750.
   PubMed Web of Science ®Google Scholar
• Aldemir-Kocabaş B, Tezcan-Karasu G, Bircan İ, et al. Evaluating the patients with thalassemia major for long-term endocrinological complications after bone marrow transplantation. Pediatr Hematol Oncol. 2014;31(7):616–623.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811–820.
   PubMed Web of Science ®Google Scholar
• Kahraman S, Beyazyurek C, Yesilipek MA, et al. Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching. Reprod Biomed Online. 2014;29(3):340–351.
   PubMed Web of Science ®Google Scholar
• Kurekci E, Kupesiz A, Anak S, et al. Hematopoietic stem cell transplantation using preimplantation genetic diagnosis and human leukocyte antigen typing for human leukocyte antigen-matched sibling donor: a Turkish multicenter study. Biol Blood Marrow Transplant. 2017;23(5):790–794.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Karasu G, Ercelen N, et al. Successful hematopoietic SCT from non-identical twins to two sisters with β-thalassemia major by using preimplantation genetic diagnosis and HLA typing. Bone Marrow Transplant. 2011;46(12):1581–1582.
   PubMed Web of Science ®Google Scholar
• Tucunduva L, Volt F, Cunha R, et al. Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases. Br J Haematol. 2015;169(1):103–110.
   PubMed Web of Science ®Google Scholar
• La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci. 2005;1054:186–195.
   PubMed Web of Science ®Google Scholar
• Karasu G, Uygun V, Daloglu H, et al. Hematopoietic stem cell transplantation from unrelated donor in children with beta thalassemia major. Biol Blood Marrow Transplant. 2018;24(3):S401–S402.
   Google Scholar
• Sodani P, Isgro A, Gaziev J, et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood. 2010;115(6):1296–1302.
   PubMed Web of Science ®Google Scholar
• Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–826.
   PubMed Web of Science ®Google Scholar
• Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813–818.
   PubMed Web of Science ®Google Scholar
• Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen. Biol Blood Marrow Transplant. 2020;26(6):1106–1112.
   PubMed Web of Science ®Google Scholar
• Yee ME, Shah A, Anderson AR, et al. Class I and II HLA antibodies in pediatric patients with thalassemia major. Transfusion. 2016;56(4):878–884.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Hazar V, Kupesiz A, et al. Peripheral blood stem cell transplantation in children with beta-thalassemia. Bone Marrow Transplant. 2001;28(11):1037–1040.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Iravani M, Ashouri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant. 2008;14(3):301–308.
   PubMed Web of Science ®Google Scholar
• Jaing TH, Hung IJ, Yang CP, et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant. 2012;47(1):33–39.
   PubMed Web of Science ®Google Scholar
• Karasu G, Uygun V, Kilic SC, et al. The cell loss after thawing in cord blood units. Blood. 2014;124(21):5833–5833.
   Web of Science ®Google Scholar
• Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831–839.
   PubMed Web of Science ®Google Scholar
• Sideri A, Neokleous N, Brunet De La Grange P, et al. An overview of the progress on double umbilical cord blood transplantation. Haematologica. 2011;96(8):1213–1220.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Montesinos P, Peled T, et al. Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation. Biol Blood Marrow Transplant. 2018;24(7):1463–1470.
   PubMed Web of Science ®Google Scholar
• Manna M, Nesci S, Andreani M, et al. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients. Bone Marrow Transplant. 1993;12(Suppl 1):70–73.
   PubMed Web of Science ®Google Scholar
• Goussetis E, Peristeri I, Kitra V, et al. HLA-matched sibling stem cell transplantation in children with β-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience. Bone Marrow Transplant. 2012;47(8):1061–1066.
   PubMed Web of Science ®Google Scholar
• Faulkner L, Uderzo C, Khalid S, et al. ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017;1(13):792–801.
   PubMed Web of Science ®Google Scholar
• Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201–1203.
   PubMed Web of Science ®Google Scholar
• Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120(19):3875–3881.
   PubMed Web of Science ®Google Scholar
• Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25(4):401–404.
   PubMed Web of Science ®Google Scholar
• Karasu G, Uygun V, Karaüzüm SB, et al., editors. Talasemi transplantında mikst kimerizm graft reddi için melirleyici mi? [Turkish]. [Oral presentation #076, Proceedings Abstract Book, p. 157, 2010]. Presented at the 6th National Bone Marrow Transplantation and Stem Cell Therapy Congress, held at Antalya, Turkey; March 4–6 2010.
   Google Scholar
• Karasu GT, Yesilipek MA, Karauzum SB, et al. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation. Pediatr Blood Cancer. 2012;58(3):453–458.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Yannucci J, Storb RF, et al. Recurrence of β-thalassemia major more than 20 years after HLA-identical sibling BMT treated successfully with donor lymphocyte infusion. Bone Marrow Transplant. 2011;46(7):1037–1038.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17–21.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Lucarelli G, et al. Treatment of iron overload in the “ex-thalassemic.” Report from the phlebotomy program. Ann NY Acad Sci. 1998;850:288–293.
   PubMed Web of Science ®Google Scholar
• Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med. 2002;136(9):667–672.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Karasu G, Kazik M, et al. Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major. Pediatr Hematol Oncol. 2010;27(5):374–379.
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Karasu G, Kaya Z, et al. A phase II, multicenter, single-arm study to evaluate the safety and efficacy of deferasirox after hematopoietic stem cell transplantation in children with β-thalassemia major. Biol Blood Marrow Transplant. 2018;24(3):613–618.
   PubMed Web of Science ®Google Scholar
• Karasu G, Uygun V, Hazar V, et al. Hematopoetic stem cell transplantation in patients with thalassemia major: better in younger. [Abstract #0166]. Presented at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation, held at Frankfurt, Germany; March 24–27, 2019. Bone Marrow Transplant. 2019;54(Suppl 1):128–129.
   Google Scholar
• Uygun V, Tayfun F, Akcan M, et al. Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients. Pediatr Hematol Oncol. 2012;29(5):461–471.
   PubMed Web of Science ®Google Scholar
• La Nasa G, Caocci G, Efficace F, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood. 2013;122(13):2262–2270.
   PubMed Web of Science ®Google Scholar
• Li CK, Chik KW, Wong GW, et al. Growth and endocrine function following bone marrow transplantation for thalassemia major. Pediatr Hematol Oncol. 2004;21(5):411–419.
   PubMed Web of Science ®Google Scholar
• Mohamed SY. Thalassemia major: transplantation or transfusion and chelation. Hematol Oncol Stem Cell Ther. 2017;10(4):290–298.
   PubMedGoogle Scholar
• John MJ, Jyani G, Jindal A, et al. Cost effectiveness of hematopoietic stem cell transplantation compared with transfusion chelation for treatment of thalassemia major. Biol Blood Marrow Transplant. 2018;24(10):2119–2126.
   PubMed Web of Science ®Google Scholar
• Sruamsiri R, Chaiyakunapruk N, Pakakasama S, et al. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program. BMC Health Serv Res. 2013;13:45
   PubMed Web of Science ®Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38(4 Suppl):S512–S521.
   PubMed Web of Science ®Google Scholar
• Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447–3452.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Robertson Z, Robinson A, et al. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant. 2010;45(5):895–900.
   PubMed Web of Science ®Google Scholar
• Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137(5):479–485.
   PubMed Web of Science ®Google Scholar
• Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323–327.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(4):552–561.
   PubMed Web of Science ®Google Scholar
• Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22(2):207–211.
   PubMed Web of Science ®Google Scholar
• Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49(7):913–920.
   PubMed Web of Science ®Google Scholar
• McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011;46(1):27–33.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Lawitschka A, Fritsch G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013;90(4):308–312.
   PubMed Web of Science ®Google Scholar
• Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program. 2011;2011:273–279.
   PubMed Web of Science ®Google Scholar
• Ozdogu H, Boga C, Yeral M, et al. Excellent outcomes of allogeneic transplantation from peripheral blood of HLA-matched related donors for adult sickle cell disease with ATLG and posttransplant cyclophosphamide-containing regimen: an update work. Bone Marrow Transplant. 2020;55(8):1647–1651.
   PubMed Web of Science ®Google Scholar
• Abraham A, Hsieh M, Eapen M, et al. Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017;23(12):2178–2183.
   PubMed Web of Science ®Google Scholar
• Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665–673.
   PubMed Web of Science ®Google Scholar
• Magnani A, Pondarre C, Bouazza N, et al. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy. Haematologica. 2020;105(5):1240–1247.
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Dalle JH, Bories D, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105(1):91–101.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Cappelli B, Scigliuolo GM, et al. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Hematol Oncol Stem Cell Ther. 2020 Mar 16;S1658-S3876(20):30034-0. DOI: 10.1016/j.hemonc.2019.12.011.
   Google Scholar
• Foell J, Kleinschmidt K, Jakob M, et al. Alternative donor: αβ/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. Hematol Oncol Stem Cell Ther. 2020;13(2):98–105.
   PubMedGoogle Scholar
• de la Fuente J, Dhedin N, Koyama T, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant. 2019;25(6):1197–1209.
   PubMed Web of Science ®Google Scholar
• Ferrari G, Cavazzana M, Mavilio F. Gene therapy approaches to hemoglobinopathies. Hematol Oncol Clin North Am. 2017;31(5):835–852.
   PubMed Web of Science ®Google Scholar
• Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol. 2016;7(5):302–315.
   PubMed Web of Science ®Google Scholar
• Coquerelle S, Ghardallou M, Rais S, et al. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic stem-cell transplantation. Hum Gene Ther. 2019;30(6):753–761.
   PubMed Web of Science ®Google Scholar
• Cavazzana M, Antoniani C, Miccio A. Gene therapy for β-hemoglobinopathies. Mol Ther. 2017;25(5):1142–1154.
   PubMed Web of Science ®Google Scholar